-
Canaccord Genuity Starts Veru, Inc. (VERU) at Buy
-
Oppenheimer Reiterates Outperform Rating on Veru, Inc. (VERU)
-
Veru reports fiscal 2025 results, plans obesity drug trial
-
Veru receives FDA clarity on enobosarm obesity drug development pathway
-
Veru, Inc. (VERU) PT Raised to $25 at Oppenheimer
-
Veru, Inc. (VERU) PT Lowered to $20 at Raymond James
-
Veru, Inc. (VERU) Misses Q3 EPS by 45c
-
Veru selects Laxxon's SPID technology for enobosarm formulation
-
Veru selects modified release enobosarm formulation for weight loss
-
Veru, Inc. (VERU) Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study
-
Veru, Inc. (VERU) Reports Positive Safety Results from Phase 2b QUALITY Study:
-
Veru, Inc. (VERU) Tops Q2 EPS by 1c
-
Veru, Inc. (VERU) PT Lowered to $4 at Oppenheimer
-
Veru, Inc. (VERU) Tops Q1 EPS by 2c
-
Oppenheimer Reiterates Outperform Rating on Veru, Inc. (VERU)
-
Veru, Inc. (VERU) Announces Positive Topline Data from Phase 2b QUALITY Clinical Study
-
Oppenheimer Reiterates Outperform Rating on Veru, Inc. (VERU) as Key Catalyst Approaches
-
Increasing unusual put option volume: RGTI NMRA VERU SDS FFIE QBTS PLNT QUBT TCOM
-
H.C. Wainwright Reiterates Buy Rating on Veru, Inc. (VERU)
-
Veru, Inc. (VERU) Sells the FC2 Female Condom (Internal Condom) Business
-
H.C. Wainwright Reiterates Buy Rating on Veru, Inc. (VERU)
-
Oppenheimer Reiterates Outperform Rating on Veru, Inc. (VERU)
-
Veru, Inc. (VERU) Misses Q3 EPS by 1c
-
Veru, Inc. (VERU) PT Lowered to $1 at Jefferies

